{
    "clinical_study": {
        "@rank": "99098", 
        "arm_group": [
            {
                "arm_group_label": "Regenexx SD", 
                "arm_group_type": "Active Comparator", 
                "description": "Bone Marrow Aspirate Concentrate injected under imaging guidance into the area of the damaged ligament."
            }, 
            {
                "arm_group_label": "Exercise Therapy", 
                "arm_group_type": "Active Comparator", 
                "description": "Subjects will be instructed in a set of appropriate rotator cuff strengthening exercises and given an instructional hand-out to take home."
            }
        ], 
        "brief_summary": {
            "textblock": "The primary objective of this study is to compare the improvement in subject-reported\n      clinical outcomes for Regenexx SD vs. Exercise Therapy treatment of partial and complete,\n      non-retracted knee ACL ligament tears, from baseline to 3 months, with continued evaluation\n      of efficacy and durability up to 24 months.\n\n      Secondary objectives include evaluation of MRI evidence of tendon repair; incidence of\n      post-operative complications, adverse events, re-injections, and surgical intervention;\n      change in pain score and use of pain medications."
        }, 
        "brief_title": "Regenexx\u2122 SD Versus Exercise Therapy for ACL Tears", 
        "completion_date": {
            "#text": "May 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Anterior Cruciate Ligament Tear", 
        "condition_browse": {
            "mesh_term": [
                "Lacerations", 
                "Rupture"
            ]
        }, 
        "detailed_description": {
            "textblock": "Prospective, randomized, controlled to include 25 subjects treated with Regenexx SD and 25\n      subjects treated with exercise therapy alone with the exercise group crossing over to the\n      injection group at 3 months.\n\n      Subjects will have a partial or complete, non-retracted ACL ligament tear as evidenced with\n      MRI.\n\n      Subjects will be enrolled within 60 days prior to Regenexx-SD injection or initiation of\n      exercise therapy and take part in follow-up visits for two years following treatment.  A\n      preoperative visit will occur at the time of enrollment; follow-up visits will occur at the\n      clinical site at 6 weeks, 3 months, 6 months, 12 months, and 24 months post injection.\n\n      The primary endpoint analysis will be conducted once all subjects reach the 3 month\n      endpoint. Subjects will continue to be followed through the 2 year endpoint with data\n      analysis performed at the 1 year and 2 year time points."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Pain, swelling, or functional disability in the affected knee with activity, having\n             failed conservative treatment (e.g. NSAIDs, physician initiated physical therapy) for\n             at least 3 months or unable to return to normal day to day activities by 6 weeks\n\n          -  Physical examination consistent with lax ACL ligament (Anterior Drawer Test)\n\n          -  Abnormal Telos Arthrometer measurement\n\n          -  Positive diagnostic MR imaging of the affected knee with at least 1/3 of the ACL\n             ligament at any area along its length having high signal on MRI PDFS/Fat Sat images.\n\n          -  Full range of motion of the affected knee (other than restriction clearly due to\n             effusion)\n\n          -  Normal range of motion of the non-treated knee\n\n          -  Is independent, ambulatory, and can comply with all post-operative evaluations and\n             visits\n\n        Exclusion Criteria:\n\n          -  A massive ACL tear or one that includes more than 2/3'rds of the ligament that's\n             retracted.\n\n          -  Previous surgery to the affected ACL (i.e. previous ACL replacement with an autograft\n             or allograft)\n\n          -  Prior ACL prolotherapy, PRP, corticosteroid injection or other injection therapy\n             within the past three months,\n\n          -  Concomitant meniscus tear or cartilage injury that occurred at the same time as the\n             as the ACL tear and which is considered a pain generator by the treating physician at\n             the time intake into the study (i.e. a meniscus tear or cartilage lesion associated\n             with an active BML).\n\n          -  Concomitant PCL, MCL, or LCL tears\n\n          -  Inflammatory or auto-immune based joint diseases or other lower extremity pathology\n             (e.g., rheumatoid arthritis, systemic lupus erythematosus, psoriatic arthritis,\n             polymyalgia, polymyositis, gout pseudogout)\n\n          -  Quinolone or Statin induced myopathy/ tendinopathy\n\n          -  Kellgren-Lawrence grade 2 or greater knee osteoarthritis\n\n          -  Significant knee extension lag compared to the opposite knee\n\n          -  Symptomatic lumbar spine pathology (e.g. radicular pain)\n\n          -  Severe neurogenic inflammation of the cutaneous nerves about the knee or thigh\n\n          -  Contraindications for MRI\n\n          -  Tested positive or has been treated for a malignancy in the past or is suspected of\n             having a malignancy or is currently undergoing radiation or chemotherapy treatment\n             for a malignancy anywhere in the body, whether adjacent to or distant from the\n             proposed injection site\n\n          -  Condition represents a worker's compensation case\n\n          -  Currently involved in a health-related litigation procedure\n\n          -  Is pregnant\n\n          -  Bleeding disorders\n\n          -  Currently taking anticoagulant or immunosuppressive medication\n\n          -  Allergy or intolerance to study medication\n\n          -  Use of chronic opioid,"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 7, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01850758", 
            "org_study_id": "RSI2013-RCT01"
        }, 
        "intervention": [
            {
                "arm_group_label": "Regenexx SD", 
                "intervention_name": "Regenexx SD", 
                "intervention_type": "Procedure"
            }, 
            {
                "arm_group_label": "Exercise Therapy", 
                "intervention_name": "Exercise Therapy", 
                "intervention_type": "Other"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "ACL", 
            "Anterior Cruciate Ligament", 
            "ACL Tear", 
            "Anterior Cruciate Ligament Tear", 
            "Partial ACL Tear"
        ], 
        "lastchanged_date": "January 7, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Broomfield", 
                    "country": "United States", 
                    "state": "Colorado", 
                    "zip": "80021"
                }, 
                "name": "Centeno-Schultz Clinic"
            }, 
            "investigator": [
                {
                    "last_name": "Christopher Centeno, MD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Ron Hanson, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "John Schultz, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Ben Newton, MD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized Controlled Trial of Regenexx\u2122 SD Versus Exercise Therapy for Treatment of Partial and Complete, Non-retracted Anterior Cruciate Ligament Tears", 
        "overall_contact": {
            "email": "studycandidate@regenexx.com", 
            "last_name": "Regenexx Information", 
            "phone": "1-888-525-3005"
        }, 
        "overall_official": {
            "affiliation": "Centeno-Schultz Clinic", 
            "last_name": "Christopher Centeno, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary endpoint for this study is the difference between treatment groups in the within patient mean change from baseline to 3 months in IKDC scores.", 
            "measure": "IKDC Subjective Knee Evaluation Score Change from Baseline", 
            "safety_issue": "No", 
            "time_frame": "Change from Baseline to 3 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01850758"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Difference between treatment groups in mean 0-10 pain scales at each follow-up timepoint", 
                "measure": "Mean Pain Scales", 
                "safety_issue": "No", 
                "time_frame": "3, 6, 12 and 24 months"
            }, 
            {
                "description": "Comparison between groups of Magnetic Resonance Evaluation of ligament repair at 3 months", 
                "measure": "Magnetic Resonance Evaluation of ligament repair", 
                "safety_issue": "No", 
                "time_frame": "3 months"
            }, 
            {
                "description": "Difference between treatment groups in mean KDC Subjective Knee Evaluation Scores at 6, 12 and 24 months.", 
                "measure": "Mean IKDC Subjective Knee Evaluation Scores", 
                "safety_issue": "No", 
                "time_frame": "6, 12 and 24 months"
            }, 
            {
                "description": "Incidence and time to resolution of post-operative complications and adverse events between treatment groups.", 
                "measure": "Incidence of complications and adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "24 months"
            }, 
            {
                "description": "Incidence of and time to re-injection and surgical revision between treatment groups.", 
                "measure": "Incidence of re-injection and surgical revision", 
                "safety_issue": "No", 
                "time_frame": "24 months"
            }, 
            {
                "description": "Difference between treatment groups in use of pain medications at each follow-up timepoint", 
                "measure": "Use of pain medications", 
                "safety_issue": "No", 
                "time_frame": "3, 6, 12 and 24 months"
            }
        ], 
        "source": "Regenerative Sciences, LLC", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Regenerative Sciences, LLC", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}